Related Experiment Video
Updated: Aug 21, 2025
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
A long-term follow-up study of diabetic foot ulcer using micronized acellular dermal matrix
Je Yeon Byeon1, Yong Seon Hwang1, Hwan Jun Choi1,2
1Department of Plastic and Reconstructive Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea.
Abstract:
Treating a diabetic foot ulcer (DFU) extending to the tendon or bone can be a challenge for physicians. Recent studies have shown positive results of micronized acellular dermal matrix (ADM) treatment for treating DFU. However, studies on such ADM with a long-term follow-up are rare. Thus, the objective of this study was to retrospectively analyse patients treated with micronized ADM with a long-term follow-up to assess the effectiveness of the treatment and determine the recurrence rate. The rate of success of complete healing was 62.96% and the time of complete healing was 86.96 days in this study. The recurrence rate of DFUs was 41.17% in the overall group. However, it was only 23.52% in the micronized ADM group. The average duration of recurrence was 720.50 ± 505.12 days. The recurrence rate was 50% in weight bearing areas such as the plantar and heel. It was 12.5% in toes and non-weight bearing areas. In conclusion, micronized ADM can be used to effectively treat DFUs that have invaded ligaments or bones. A close follow-up of weight bearing area wounds will allow us to identify and treat recurrence early.
Insights
Micronized acellular dermal matrix (ADM) effectively treats deep diabetic foot ulcers (DFUs). While recurrence occurs, ADM shows lower rates, especially in non-weight-bearing areas, highlighting its therapeutic potential.
Area of Science:
- Regenerative Medicine
- Wound Healing
- Diabetic Complications
Background:
- Diabetic foot ulcers (DFUs) extending to tendon or bone present significant treatment challenges.
- Micronized acellular dermal matrix (ADM) shows promise for DFU treatment, but long-term follow-up data is limited.
Purpose of the Study:
- To retrospectively analyze patients treated with micronized ADM for DFUs.
- To assess the long-term effectiveness and recurrence rates of micronized ADM in DFU treatment.
Main Methods:
- Retrospective analysis of patients with DFUs treated with micronized ADM.
- Evaluation of complete healing rates, time to healing, and recurrence rates.
- Analysis of recurrence rates based on wound location (weight-bearing vs. non-weight-bearing areas).
Main Results:
- Complete healing rate was 62.96% with an average healing time of 86.96 days.
- Overall DFU recurrence rate was 41.17%, significantly lower at 23.52% in the micronized ADM group.
- Recurrence was higher in weight-bearing areas (50%) compared to non-weight-bearing areas (12.5%).
Conclusions:
- Micronized ADM is effective for treating DFUs involving tendon or bone.
- Close monitoring of weight-bearing DFU sites is crucial for early detection and management of recurrence.
